But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide-1 receptor agonists) — the ...
Tv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 22,500 shares, a decrease ...
The global obesity epidemic represents one of the most pressing public health challenges of our time. With nearly ...
NN-9847 is under development for the treatment of obesity and type 2 diabetes. It is a glucagon like peptide-1 (GLP-1) and amylin receptor co-agonist, administered through oral route in the form of ...
It is administered through subcutaneous route. The drug candidate acts by targeting glucagon like peptide 1 receptor (GLP-1R) and gastric inhibitory polypeptide (GIP). It is being developed based on ...